HealthMore in Health→
Neurocrine’s $2.9 billion Soleno deal adds an approved rare-disease drug
Neurocrine Biosciences is buying Soleno Therapeutics for $2.9 billion, gaining an approved treatment for a rare disease associated with insatiable hunger.
Key Takeaways
- Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion.
- The acquisition adds an approved treatment for a rare disease that causes insatiable hunger.
DE
DT Editorial Team··via statnews.com